37
Participants
Start Date
April 15, 2015
Primary Completion Date
December 19, 2017
Study Completion Date
December 19, 2017
Radium-223 dichloride (Xofigo, BAY88-8223)
Xofigo was approved in the US and EU for the following indication: Xofigo is indicated for the treatment of adults with castration-resistant prostate cancer, symptomatic bone metastases and no known visceral metastases. Xofigo is contraindicated in women who are or may become pregnant.
Stockholm
Lead Sponsor
Bayer
INDUSTRY